LXEO Stock Overview
Operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lexeo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.86 |
| 52 Week High | US$22.33 |
| 52 Week Low | US$9.00 |
| Beta | 0 |
| 11 Month Change | -0.93% |
| 3 Month Change | -5.23% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 47.86% |
Recent News & Updates
We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Jun 18
Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off
Apr 09Shareholder Returns
| LXEO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.2% | 1.0% | -0.2% |
| 1Y | n/a | 10.7% | 22.9% |
Return vs Industry: Insufficient data to determine how LXEO performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how LXEO performed against the US Market.
Price Volatility
| LXEO volatility | |
|---|---|
| LXEO Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: LXEO's share price has been volatile over the past 3 months.
Volatility Over Time: LXEO's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 58 | R. Townsend | www.lexeotx.com |
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease.
Lexeo Therapeutics, Inc. Fundamentals Summary
| LXEO fundamental statistics | |
|---|---|
| Market cap | US$482.32m |
| Earnings (TTM) | -US$69.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.1x
P/E RatioIs LXEO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LXEO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$52.43m |
| Gross Profit | -US$52.43m |
| Other Expenses | US$16.99m |
| Earnings | -US$69.42m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.11 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LXEO perform over the long term?
See historical performance and comparison